1. Home
  2. NGNE vs WLFC Comparison

NGNE vs WLFC Comparison

Compare NGNE & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$25.43

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Logo Willis Lease Finance Corporation

WLFC

Willis Lease Finance Corporation

N/A

Current Price

$46.99

Market Cap

801.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
WLFC
Founded
2003
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
801.2M
IPO Year
2014
1997

Fundamental Metrics

Financial Performance
Metric
NGNE
WLFC
Price
$25.43
$46.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
2
Target Price
★ $77.88
$70.50
AVG Volume (30 Days)
★ 342.8K
207.1K
Earning Date
11-20-2026
11-03-2026
Dividend Yield
N/A
★ 1.28%
EPS Growth
★ 0.93
N/A
EPS
N/A
★ 2.86
Revenue
N/A
★ $569,223,000.00
Revenue This Year
N/A
$12.51
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$16.66
Revenue Growth
N/A
★ N/A
52 Week Low
$15.93
$12.67
52 Week High
$43.66
$81.54

Technical Indicators

Market Signals
Indicator
NGNE
WLFC
Relative Strength Index (RSI) 47.84 70.11
Support Level $24.88 $18.05
Resistance Level $28.47 $51.95
Average True Range (ATR) 2.50 2.62
MACD 0.38 0.26
Stochastic Oscillator 35.88 85.45

Price Performance

Historical Comparison
NGNE
WLFC

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

Share on Social Networks: